A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and
A phase 2 trial of Izalontamab brengitecan, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT06475300 by Sichuan Baili Pharmaceutical Co., Ltd., with 570 participants planned, started 2024-06-25 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1, PD-1 Monoclonal Antibody, Pemetrexed Disodium. Conditions listed: Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other
Shares Izalontamab brengitecan, Nasopharyngeal carcinoma, SystImmune / Sichuan Biokin, Small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Pemetrexed, Small-cell lung cancer.
- TrialA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Pemetrexed, Small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.